WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

  • WJPPS: NOVEMBER ISSUE PUBLISHED
  • NOVEMBER 2024 Issue has been successfully launched on NOVEMBER 2024.

Abstract

COMBINATION OF ASPIRIN, CLOPIDOGREL BISULPHATE AND ATORVASTATIN CALCIUM BILAYER TABLETS FOR HEART DISEASES

Natarajan R*., Abirami M., Sreekanth K., Sharadhamani G., Ananda Thangadurai S.,

ABSTRACT

Multilayered tablets possess various benefits, like improves its efficacy and safety by controlling the rate, time, and place of release of drugs in the body and the ability to prevent incompatibility between drugs and excipients; and by providing multiple release kinetics mechanisms. The ternary combination is used for atherosclerotic patients suffering from various heart diseases. Clinical trials showed that combination therapy when used in dyslipidaemic patient with coronary heart disease reduced cardiovascular events. Bilayer tablets containing immediate release layer of Aspirin, Clopidogrel Bisulphate and sustained release layer of Atorvastatin Calcium were prepared by dry granulation method and their evaluation were carried out. The formulated tablets (F1, F2 and F3) were compared with marketed capsules containing the same strength of Aspirin, Clopidogrel Bisulphate and Atorvastatin Calcium. The in vitro drug release studies from the developed formulation (F3) showed up to 81.88% up to 12 hours in sustained release manner. Then the similarity factor (f2) was compared the formulation (F3) with Innovator capsules and it was found to be similar.

Keywords: Bi-layer tablets, Ternary combination drug, Heart diseases, Similarity factor, Sustained release.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More